跳转至内容
Merck

Y0001094

醋氯芬酸

European Pharmacopoeia (EP) Reference Standard

别名:

Aceclofenac, 2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid carboxymethyl ester;

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C16H13Cl2NO4
CAS号:
分子量:
354.18
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

aceclofenac

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

OC(=O)COC(=O)Cc1ccccc1Nc2c(Cl)cccc2Cl

InChI

1S/C16H13Cl2NO4/c17-11-5-3-6-12(18)16(11)19-13-7-2-1-4-10(13)8-15(22)23-9-14(20)21/h1-7,19H,8-9H2,(H,20,21)

InChI key

MNIPYSSQXLZQLJ-UHFFFAOYSA-N

基因信息

human ... PTGS2(5743)

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Aceclofenac for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

Non-steroidal, anti-inflammatory drug (NSAID), with selectivity for COX-2 over COX-1.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Skull and crossbonesEnvironment

警示用语:

Danger

危险声明

危险分类

Acute Tox. 3 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Eye Irrit. 2

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Viney Chawla et al.
Colloids and surfaces. B, Biointerfaces, 92, 293-298 (2012-01-10)
Solid lipid nanoparticles (SLN) of aceclofenac were prepared using Taguchi experimental design by Trotta method. The prepared SLN were formulated into a gel preparation, using carbopol 940. Gels were evaluated for drug content, bioadhesion and their stability against change of
Sanjay Dey et al.
Expert opinion on drug delivery, 9(9), 1041-1050 (2012-07-14)
The objective of the present study was to develop bilayer tablets of aceclofenac that are characterized by initial burst drug release followed by sustained release of drug. The fast-release layer of the bilayer tablet was formulated using microcrystaline cellulose (MCC)
Anil Pareek et al.
The journal of pain : official journal of the American Pain Society, 12(5), 546-553 (2011-02-01)
The efficacy and safety of aceclofenac control release (CR) tablets was compared with conventional aceclofenac tablets in patients with knee osteoarthritis (OA). This was a double-blind, double-dummy, randomized, parallel group multicentric study conducted at 6 centers. Two hundred and eighty
Sandipan Dasgupta et al.
Expert opinion on drug delivery, 10(4), 411-420 (2013-01-16)
The aim of the present study was to investigate the potential of a nanoemulsion for topical delivery of aceclofenac using different excipients having optimum emulsifying ability rather than their solubilizing capacity. The oil-in-water nanoemulsions were prepared by screening the excipients
Rajesh Katara et al.
Colloids and surfaces. B, Biointerfaces, 103, 455-462 (2012-12-25)
The purpose of this study was to prepare Eudragit RL 100-based nanoparticles of aceclofenac by nanoprecipitation and evaluate the particle size, zeta potential, drug entrapment, particle morphology; in vitro drug release and in vivo efficacy. Change in drug-polymer ratio from

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持